Effects of β2-Adrenergic Agonists on Risk of Parkinson's Disease in COPD: A Population-Based Study.
Wenjia ChenMohsen SadatsafaviHamid TavakoliAli SamiiMahyar EtminanPublished in: Pharmacotherapy (2020)
Use of β2 -agonists does not appear to affect the risk of PD in a real-world COPD population.